CNS Pharmaceuticals (CNSP) said Tuesday it has acquired from Cortice Biosciences orphan drug designation for late stage abeotaxane TPI 287 as a potential treatment for glioblastoma multiforme.
The company said it aims to begin enrolling patients for a phase 2 study around the end of this year. Clinical data from a phase 1 trial showed that TPI 287 has the potential to cross the blood brain barrier and treat central nervous system tumors, according to the company.
TPI 287 was previously granted orphan drug designation by the US Food and Drug Administration in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, the company said.
The company's shares surged past 120% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。